Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valemetostat and Atezolizumab in Extensive-Stage Small Cell Lung Cancer
NCT06807632Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of valemetostat in small cell lung cancer (SCLC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Recommended Phase II Dose at 1 year. Started Jan 2025; status: recruiting.
02
Drugs
valemetostat
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06807632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06807632.